LEIDEN, The Netherlands, July 13,
2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming")
(Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report
its preliminary (unaudited) second quarter and first half 2023
financial results, for the period ended June
30, on Thursday, August 3,
2023.
Pharming will host a presentation for analysts and investors at
13:30 CEST/07:30 EDT on August 3,
2023.
Dial in details for the presentation are detailed below.
Webcast Link:
https://webcast.openbriefing.com/pharming1h23/
Conference Call Dial-in Details:
Netherlands: +31 85 888 7233
United States (Local): +1 646 664
1960
United Kingdom (Local): +44 20
3936 2999
Global Dial-In Numbers
Access Code: 760288
About Pharming Group N.V.
Pharming Group N.V.
(Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global
biopharmaceutical company dedicated to transforming the lives of
patients with rare, debilitating, and life-threatening diseases.
Pharming is commercializing and developing an innovative portfolio
of protein replacement therapies and precision medicines, including
small molecules, biologics, and gene therapies that are in early to
late-stage development. Pharming is headquartered in Leiden,
Netherlands, and has employees
around the globe who serve patients in over 30 markets in
North America, Europe, the Middle
East, Africa, and
Asia-Pacific.
For more information, visit www.pharming.com and find us on
LinkedIn.
For further public information, contact:
Pharming Group, Leiden, The
Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications
T: +1 (908) 705 1696
Heather Robertson, Investor
Relations & Corporate Communications Manager
E: investor@pharming.com
FTI Consulting, London,
UK
Victoria Foster
Mitchell/Alex Shaw/Amy
Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pharming-group-to-report-second-quarter-and-first-half-2023-financial-results-on-august-3-301875804.html
SOURCE Pharming Group N.V.
